Literature DB >> 20861207

Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

S P Ardoin1, L E Schanberg, C Sandborg, E Yow, H X Barnhart, K l Mieszkalski, N T Ilowite, E von Scheven, A Eberhard, D M Levy, Y Kimura, E Silverman, S L Bowyer, L Punaro, N G Singer, D D Sherry, D McCurdy, M Klein-Gitelman, C Wallace, R Silver, L Wagner-Weiner, G C Higgins, H I Brunner, L K Jung, L Imundo, J B Soep, A M Reed.   

Abstract

As part of the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Trial, a prospective multicenter cohort of 221 children and adolescents with systemic lupus erythematosus (SLE) (mean age 15.7 years, 83% female) underwent baseline measurement of markers of cardiovascular risk, including fasting levels of high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TG), lipoprotein A (Lpa), homocysteine and high-sensitivity C-reactive protein (hs-CRP). A cross-sectional analysis of the baseline laboratory values and clinical characteristics of this cohort was performed. Univariable relationships between the cardiovascular markers of interest and clinical variables were assessed, followed by multivariable linear regression modeling. Mean levels of LDL, HDL, Lpa, TG, hs-CRP and homocysteine were in the normal or borderline ranges. In multivariable analysis, increased Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), prednisone dose, and hypertension (HTN) were independently associated with higher LDL levels. Higher hs-CRP and creatinine clearance were independently related to lower HDL levels. Higher body mass index (BMI), prednisone dose, and homocysteine levels were independently associated with higher TG levels. Only Hispanic or non-White status predicted higher Lpa levels. Proteinuria, higher TG and lower creatinine clearance were independently associated with higher homocysteine levels, while use of multivitamin with folate predicted lower homocysteine levels. Higher BMI, lower HDL, and longer SLE disease duration, but not SLEDAI, were independently associated with higher hs-CRP levels. The R(2) for these models ranged from 7% to 23%. SLE disease activity as measured by the SLEDAI was associated only with higher LDL levels and not with hs-CRP. Markers of renal injury (HTN, proteinuria, and creatinine clearance) were independently associated with levels of LDL, HDL, and homocysteine, highlighting the importance of renal status in the cardiovascular health of children and adolescents with SLE. Future longitudinal analysis of the APPLE cohort is needed to further examine these relationships.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861207      PMCID: PMC4049625          DOI: 10.1177/0961203310373937

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  46 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

Review 4.  Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Significance of C-reactive protein elevation in the pretreatment stage of systemic lupus erythematosus.

Authors:  T Inoue; Y Kanayama; N Katoh; A Ohe; K Amatsu; M Okamura; T Horiguchi
Journal:  Scand J Rheumatol       Date:  1981       Impact factor: 3.641

6.  C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Earl S Ford; Wayne H Giles; Gary L Myers; Nader Rifai; Paul M Ridker; David M Mannino
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

Review 7.  Homocysteine and cardiovascular disease: a review of the evidence.

Authors:  Anthony S Wierzbicki
Journal:  Diab Vasc Dis Res       Date:  2007-06       Impact factor: 3.291

8.  Prevalence of conventional risk factors in patients with coronary heart disease.

Authors:  Umesh N Khot; Monica B Khot; Christopher T Bajzer; Shelly K Sapp; E Magnus Ohman; Sorin J Brener; Stephen G Ellis; A Michael Lincoff; Eric J Topol
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

Review 9.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

10.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

View more
  19 in total

Review 1.  Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention.

Authors:  M Wigren; J Nilsson; M J Kaplan
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

Review 2.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

3.  The vascular phenotype of children with systemic lupus erythematosus.

Authors:  Catherine Quinlan; Jameela Kari; Clarissa Pilkington; John Deanfield; Rukshana Shroff; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-05-23       Impact factor: 3.714

4.  Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.

Authors:  Stacy P Ardoin; Laura Eve Schanberg; Christy I Sandborg; Huiman X Barnhart; Greg W Evans; Eric Yow; Kelly L Mieszkalski; Norman T Ilowite; Anne Eberhard; Lisa F Imundo; Yuki Kimura; Deborah Levy; Emily von Scheven; Earl Silverman; Suzanne L Bowyer; L Punaro; Nora G Singer; David D Sherry; Deborah K McCurdy; Marissa Klein-Gitelman; Carol Wallace; Richard M Silver; Linda Wagner-Weiner; Gloria C Higgins; Hermine I Brunner; Lawrence Jung; Jennifer B Soep; Ann M Reed; Susan D Thompson
Journal:  Ann Rheum Dis       Date:  2013-02-22       Impact factor: 19.103

Review 5.  Adult outcomes of childhood-onset rheumatic diseases.

Authors:  Aimee Hersh; Emily von Scheven; Ed Yelin
Journal:  Nat Rev Rheumatol       Date:  2011-04-12       Impact factor: 20.543

6.  Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.

Authors:  L B Lewandowski; L E Schanberg; N Thielman; A Phuti; A A Kalla; I Okpechi; P Nourse; P Gajjar; G Faller; P Ambaram; H Reuter; G Spittal; C Scott
Journal:  Lupus       Date:  2016-08-19       Impact factor: 2.911

Review 7.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

8.  Dyslipidemia in patients with systemic lupus erythematosus: Association with disease activity and B-type natriuretic peptide levels.

Authors:  Jiangshui Yuan; L I Li; Zhaoyan Wang; Weiqing Song; Zongliang Zhang
Journal:  Biomed Rep       Date:  2015-11-18

Review 9.  Dyslipidemia in systemic lupus erythematosus.

Authors:  Melinda Zsuzsanna Szabó; Peter Szodoray; Emese Kiss
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 10.  Pediatric SLE--towards a comprehensive management plan.

Authors:  Hermine I Brunner; Jennifer Huggins; Marisa S Klein-Gitelman
Journal:  Nat Rev Rheumatol       Date:  2011-03-08       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.